Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?

被引:258
作者
Shinaberger, Christian S. [1 ,4 ]
Greenland, Sander [4 ]
Kopple, Joel D. [2 ,3 ,5 ]
Van Wyck, David [6 ,8 ]
Mehrotra, Rajnish [2 ,3 ]
Kovesdy, Csaba P. [7 ]
Kalantar-Zadeh, Kamyar [1 ,2 ,3 ,4 ]
机构
[1] Harbor UCLA Med Ctr, Harold Simmons Ctr Kidney Dis Res & Epidemiol, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
[2] Harbor UCLA Med Ctr, Div Nephrol & Hypertens, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA
[5] Univ Calif Los Angeles, Sch Publ Hlth, Dept Family Hlth, Los Angeles, CA 90024 USA
[6] Da Vita Inc, El Segundo, CA USA
[7] Salem VA Med Ctr, Salem, VA USA
[8] Arizona Hlth Sci Ctr, Arizona Ctr Aging, Tucson, AZ 85724 USA
关键词
D O I
10.3945/ajcn.2008.26665
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Dietary restrictions to control serum phosphorus, which are routinely recommended to persons with chronic kidney disease, are usually associated with a reduction in protein intake. This may lead to protein-energy wasting and poor survival. Objective: We aimed to ascertain whether a decline in serum phosphorus and a concomitant decline in protein intake are associated with an increase in the risk of death. Design: In a 3-y study (7/2001-6/2004) of 30 075 prevalent maintenance hemodialysis (MHD) patients, we examined changes in serum phosphorus and in normalized protein nitrogen appearance (nPNA), a surrogate of dietary protein intake, during the first 6 mo and the subsequent mortality. Four groups of MHD patients were defined on the basis of the direction of the changes in serum phosphorus and nPNA. Results: Baseline phosphorus had a J-shaped association with mortality, whereas higher baseline nPNA was linearly associated with greater survival. Compared with MHD patients whose serum phosphorus and nPNA both rose over 6 mo, those whose serum phosphorus decreased but whose nPNA increased had greater survival, with a case mix-adjusted death risk ratio of 0.90 (95% confidence limits: 0.86, 0.95; P < 0.001), whereas those whose phosphorus increased but whose nPNA decreased or those whose phosphorus and nPNA both decreased had worse mortality with a risk ratio of 1.11 (1.05,1.17; P < 0.001) and 1.06 (1.01,1.12; P = 0.02), respectively. Conclusions: The risk of controlling serum phosphorus by restricting dietary protein intake may outweigh the benefit of controlled phosphorus and may lead to greater mortality. Additional studies including randomized controlled trials should examine whether non-dietary control of phosphorus or restriction of nonprotein sources of phosphorus is safer and more effective. Am J Clin Nutr 2008; 88: 1511-8.
引用
收藏
页码:1511 / 1518
页数:8
相关论文
共 42 条
[1]   Left ventricular hypertrophy: Is hyperphosphatemia among dialysis patients a risk factor? [J].
Achinger, Steven G. ;
Ayus, Juan Carlos .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 :S255-S261
[2]  
BLOCK G, 2005, KIDNEY INT S, pS13
[3]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[4]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[5]   Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetites [J].
Carrero, Juan Jesus ;
Qureshi, Abdul Rashid ;
Axelsson, Jonas ;
Avesani, Carla Maria ;
Suliman, Mohammed E. ;
Kato, Sawako ;
Barany, Peter ;
Snaedal-Jonsdottir, Sunna ;
Alvestrand, Anders ;
Heimburger, Olof ;
Lindholm, Bengt ;
Stenvinkel, Peter .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (03) :695-701
[6]   Hyperphosphatemia in dialysis patients: The therapeutic role of lanthanurn carbonate [J].
Cozzolino, M. ;
Brancaccio, D. .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2007, 30 (04) :293-300
[7]   FLEXIBLE REGRESSION-MODELS WITH CUBIC-SPLINES [J].
DURRLEMAN, S ;
SIMON, R .
STATISTICS IN MEDICINE, 1989, 8 (05) :551-561
[8]   A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease [J].
Fouque, D. ;
Kalantar-Zadeh, K. ;
Kopple, J. ;
Cano, N. ;
Chauveau, P. ;
Cuppari, L. ;
Franch, H. ;
Guarnieri, G. ;
Ikizler, T. A. ;
Kaysen, G. ;
Lindholm, B. ;
Massy, Z. ;
Mitch, W. ;
Pineda, E. ;
Stenvinkel, P. ;
Trevinho-Becerra, A. ;
Wanner, C. .
KIDNEY INTERNATIONAL, 2008, 73 (04) :391-398
[9]   FGF-23 is elevated by chronic hyperphosphatemia [J].
Gupta, A ;
Winer, K ;
Econs, MJ ;
Marx, SJ ;
Collins, MT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (09) :4489-4492
[10]   Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease [J].
Gutierrez, O ;
Isakova, T ;
Rhee, E ;
Shah, A ;
Holmes, J ;
Collerone, G ;
Jüppner, H ;
Wolf, M .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :2205-2215